An orphan disease is characterized by its rarity, leading to a lack of interest from   pharmaceutical industries and medical researchers due to limited financial viability.  Consequently, the etiopathology and causative agents of such diseases remain unidentified, and specific drug therapies are unavailable. Treatment relies on the clinical experience and  intuition of individual physicians, with no standardized protocol or sufficient patient data for  validation. Toxic Epidermal Necrolysis (TEN) is one such orphan disease, with an incidence of  1 to 1.5 per million. It often results from severe hypersensitivity reactions to drugs or infections,  causing the immune system to destroy the epidermal layer, leading to multiorgan failure and a  high mortality rate. This case highlights the complexities and controversies in managing TEN.  Despite numerous specialists' involvement, her treatment led to a legal battle, culminating in a significant compensation award due to alleged medical negligence.